Allurion Technologies Inc. focuses on ending obesity with a weight loss platform to treat people who are overweight. Its platform, the Allurion Program, features swallowable and procedure-less intragastric balloon for weight loss (the Allurion Balloon) and offers access to AI-powered remote patient monitoring tools, a proprietary behavior change program, secure messaging, and video telehealth that are delivered by the Allurion Virtual Care Suite. The company is headquartered in Natick, Massachusetts.

Allurion Technologies Inc.

Allurion was founded in 2009 with one mission: end obesity. The Allurion Program combines medical, digital, and nutritional approaches and engages an entire team to jumpstart weight loss and form lifelong healthy habits.

Allurion has already helped thousands of people around the world lose weight, develop lifelong healthy habits, and transform their lives, with over 100,000 balloons placed, and over 1,000,000kg lost worldwide.

10X Capital

Runway Growth Capital

Cogepa

The Family

IDO Investments

Romulus Capital

Novalis LifeSciences

Segulah Medical Acceleration

Jose Almeida

Allurion Technologies

Tune in to this episode of BBC 5 Live Breakfast in the UK, where Dr. Shantanu Gaur explains how the Allurion Balloon works, Prof. Richard Welbourn discusses the growing need for the Allurion Balloon within the UK’s National Health Service (NHS), and we meet Donna, the first ever NHS patient to receive the Allurion Balloon, which helped her lose an amazing 16kg.

Listen to the interview here [7mins 52s]: https://lnkd.in/es_M_FJe

#Allurion #AllurionProgram #Obesity #WeightLoss #Healthcare #GastricBalloon #AllurionVCS #VirtualCareSuite #BBC

With secure and enhanced communication between your clinic and your patients, the Allurion Virtual Care Suite is designed to make it easy to build trust, personalize care, and engage patients for longer in their program.

Explore our range of VCS plans here: https://lnkd.in/dyMH_H6k 

*Allurion online survey to VCS users - May 2023 - n=67 respondents. 

#Allurion #AllurionProgram #Obesity #WeightLoss #Healthcare #GastricBalloon #AllurionVCS #VirtualCareSuite

In case you missed it…

Allurion was recently featured in an array of UK publications as the Somerset NHS Foundation Trust became the first non-private sector organization in the world to introduce the Allurion Gastric Balloon to its patients.

Meet David Pulford from Somerset in the UK. He was one of the first patients to receive the Allurion Gastric Balloon through the NHS at Musgrove Park Hospital, where the BBC was in attendance to document and broadcast this milestone in healthcare.

To read the BBC article about David’s Allurion Balloon placement experience, click here: https://lnkd.in/eKWNuKQP

#Allurion #AllurionProgram #AllurionPartner #Obesity #WeightLoss #GastricBalloon #Healthcare #MedTech #MedicalDevice #NHS #PR #BBC

Made of durable yet flexible polyurethane and crafted to the shape of the stomach, the Allurion Balloon can help patients to lose 10-15% of their total body weight in approximately four months.*

Transform your offering by becoming an Allurion clinic partner today: https://lnkd.in/dtGSv5iq 

*Ienca et al. Obes Surg. 2020 2. Vantanasiri et al. Obes Surg 2020, 3. Ienca, Presented at TOS Obesity Week, 2020.

#Allurion #AllurionProgram #Obesity #WeightLoss #Healthcare #GastricBalloon

We’re excited to announce that we will be participating in the BTIG Snowbird MedTech, Digital Health, Life Science and Diagnostic Tools Conference taking place February 12 - 14, 2024.

Shantanu Gaur, Founder & CEO, and Christopher Geberth, Chief Financial Officer, will attend and be available for investor 1x1 meetings.

Click here to read the press release: https://lnkd.in/e9KW56uv 

#Allurion #AllurionProgram #Healthcare #GastricBalloon #BTIGSnowbirdConference

Our AI-powered weight-loss companion, Coach Iris, is designed to be there for your patients 24/7.

Built in close collaboration with leading global weight-management professionals and Allurion’s behavioral scientists, Coach Iris is available on our VCS+ and VCS Custom plans and can instantly expand the care team by providing always-on support, education, and motivation to patients.

Explore our VCS+ and VCS Custom plans to unlock access here: https://lnkd.in/dyMH_H6k  

#Allurion #AllurionProgram #Obesity #WeightLoss #Healthcare #GastricBalloon #AllurionVCS #AllurionVirtualCareSuite #AIinHealthcare

We are delighted to welcome Brendan Gibbons to Allurion as our new Chief Legal Officer and corporate secretary. 
 
Brendan joins Allurion with nearly 20 years’ experience as a chief legal and compliance officer at three separate public companies. In this new role, Brendan will lead Allurion's legal and compliance strategies, playing a pivotal part in guiding our global expansion and upholding our commitment to deliver safe and effective weight loss solutions.
 
Welcome, Brendan!
 
Click here to read the full press release: https://lnkd.in/eWGFp-yA 

#Allurion #AllurionProgram #Obesity #WeightLoss #GastricBalloon #Healthcare #MedTech #MedicalDevice #AllurionPR

The Allurion Program is a holistic weight-loss program centered around the world's first and only gastric balloon that does not require surgery, endoscopy or anesthesia**.

Combined with behavior change support to help your clinic team deliver more effective results for patients, the Allurion Program can result in an average total body weight loss of 10-15% for patients in just 16 weeks*.

Become an Allurion clinic partner today: https://lnkd.in/dtGSv5iq 

#Allurion #AllurionProgram #Obesity #WeightLoss #Healthcare #GastricBalloon

*Results at 16 weeks. Raftopoulos, I et al Holyoke Medical Center. Holyoke, MA An Intensive 52 Week Nutritional, Exercise and Behavior Modification Program: Comparing With or Without the Allurion IGB Presented at ASMBS 2018
**In rare cases, the Allurion Balloon may require endoscopic or surgical intervention for removal.

The Allurion Virtual Care Suite is a dynamic weight-loss management suite powered by artificial intelligence and designed to drive all your weight-loss programs to maximize your patient outcomes and satisfaction.

Remote patient monitoring, telehealth and improved care team collaboration – all under one digital umbrella.

Start with the Allurion VCS for free: https://lnkd.in/dyMH_H6k

#Allurion #AllurionProgram #Obesity #WeightLoss #Healthcare #GastricBalloon #AllurionVCS

	Dec '20	Dec '21	Dec '22	Dec '23
net income	-5.17K -	-12.39M 239,520.82%	-37.74M 204.73%	-82.30M 118.06%
depreciation and amortization		707K -	2.00M 182.74%	746K 62.68%
deferred income tax		665K -	1.27M 91.73%	-10.21M 900.63%
stock based compensation		313K -	437K 39.62%	8.36M 1,812.36%
change in working capital	5.13K -	-1.27M 24,934.44%	-13.79M 981.41%	194K 101.41%
accounts receivables		-707K -	-22.82M 3,127.30%	-1.32M 94.22%
inventory		-1.28M -	-1.15M 10.51%	-3.71M 222.17%
accounts payables		-488K -	3.32M 781.15%	4.66M 40.31%
other working capital	5.13K -	1.21M 23,370.98%	6.86M 468.88%	553K 91.93%
other non cash items	-0.00 -	-2.35M 788,465,024,047,825,682,432%	840K 135.70%	19.23M 2,189.64%
net cash provided by operating activities	-35.00 -	-14.33M 40,939,900.00%	-46.98M 227.87%	-63.98M 36.19%
investments in property plant and equipment		-912K -	-1.55M 69.96%	-1.61M 3.61%
acquisitions net
purchases of investments		-862.50M -
sales maturities of investments
other investing activites		862.50M -
net cash used for investing activites		-912K -	-1.55M 69.96%	-1.61M 3.61%
debt repayment	-170K -	-29.40M 17,191.76%	-750K 97.45%	-55.77M 7,336.40%
common stock issued	25K -	864.13M 3,456,421.56%		213K -
common stock repurchased			-776.54M -
dividends paid
other financing activites	-147.88K -	-805.79M 544,812.52%	807.83M 200.25%	151.55M 81.24%
net cash used provided by financing activities	47.13K -	28.95M 61,321.75%	30.54M 5.50%	95.99M 214.33%
effect of forex changes on cash				-46K -
net change in cash	47.09K -	13.70M 29,001.72%	-17.99M 231.30%	30.35M 268.68%
cash at beginning of period		12.31M -	26.02M 111.30%	7.68M 70.46%
cash at end of period	47.09K -	26.02M 55,149.52%	8.02M 69.16%	38.04M 374.10%
operating cash flow	-35.00 -	-14.33M 40,939,900.00%	-46.98M 227.87%	-63.98M 36.19%
capital expenditure		-912K -	-1.55M 69.96%	-1.61M 3.61%
free cash flow	-35.00 -	-15.24M 43,545,614.29%	-48.53M 218.42%	-65.59M 35.15%

ALUR

NYSE:ALUR

Allurion Technologies Inc.

Last Close

0.68

30/08 20:00

Market Cap

64.25M

Beta: 0.01

Volume Today

121.04K

Avg: 24.32K

PE Ratio

−1.50

PFCF: −2.16

Preview